Zorifertinib
- Generic Name
- Zorifertinib
- Brand Names
- 泽瑞尼
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients with Central Nervous System (CNS) Metastases
Phase 2
Completed
- Conditions
- EGFR Gene MutationNon-small Cell Lung CancerBrain Metastases
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03653546
- Locations
- 🇨🇳
China site, Tianjin, China
🇨🇳China site 0123, Jinan, Shandong, China
🇰🇷Korea Site, Seoul, Korea, Republic of
Phase II Umbrella Study Directed by Next Generation Sequencing
Phase 2
Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- LYZZ Alpha Holding Ltd
- Target Recruit Count
- 15
- Registration Number
- NCT03360929
- Locations
- 🇨🇳
0004, Wuhan, Hubei, China
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇨🇳0003, Hangzhou, Zhejiang, China
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT02228369
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath